Literature DB >> 17202449

Medicare and erythropoietin.

Robert Steinbrook1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202449     DOI: 10.1056/NEJMp068296

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Hemoglobin and hematocrit at the end of hemodialysis: a better way to adjust erythropoietin dose?

Authors:  Erika B Rangel; Maria Claudia Andreoli; Ana Cristina C Matos; Nadia K Guimarães-Souza; Ana Cláudia Mallet; Fabiana D Carneiro; Bento C Santos
Journal:  J Artif Organs       Date:  2010-02-19       Impact factor: 1.731

2.  Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Authors:  Dawn L Hershman; Donna L Buono; Jennifer Malin; Russell McBride; Wei Yann Tsai; Alfred I Neugut
Journal:  J Natl Cancer Inst       Date:  2009-11-10       Impact factor: 13.506

Review 3.  Anemia treatment in chronic kidney disease: shifting uncertainty.

Authors:  Marc A Pfeffer
Journal:  Heart Fail Rev       Date:  2008-04-10       Impact factor: 4.214

Review 4.  HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing.

Authors:  Ingrid V Bassett; Claire Farel; Emily D Szmuilowicz; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

5.  Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.

Authors:  Kamyar Kalantar-Zadeh; Grace H Lee; Jessica E Miller; Elani Streja; Jennie Jing; John A Robertson; Csaba P Kovesdy
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

6.  Erythropoietin use and abuse.

Authors:  M Joseph John; Vineeth Jaison; Kunal Jain; Naveen Kakkar; Jubbin J Jacob
Journal:  Indian J Endocrinol Metab       Date:  2012-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.